FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Finn Bengtsson

Research Profile

Living Beings

Procedures

Disorders

Hepatic Encephalopathy

Chemicals & Drugs

Anatomy

Brain

Activities & Behaviors

Concepts & Ideas

Co-author Network

Publications

TOP 3
Louise Karlsson; Christoph Hiemke; Björn Carlsson; Martin Josefsson; Johan Ahlner; Finn Bengtsson; Ulrich Schmitt; Fredrik C Kugelberg
Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model.
Maria D Chermá; Johan Ahlner; Finn Bengtsson; Per A Gustafsson
Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study.
Maria Kingbäck; Björn Carlsson; Johan Ahlner; Finn Bengtsson; Fredrik C Kugelberg
Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague-Dawley and Dark Agouti rats.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Finn Bengtsson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Louise Karlsson; Christoph Hiemke; Björn Carlsson; Martin Josefsson; Johan Ahlner; Finn Bengtsson; Ulrich Schmitt; Fredrik C Kugelberg
Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model.
Psychopharmacology 2011;215(2):367-77.
2011: Maria D Chermá; Johan Ahlner; Finn Bengtsson; Per A Gustafsson
Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study.
Journal of clinical psychopharmacology 2011;31(1):98-102.
2011: Maria Kingbäck; Björn Carlsson; Johan Ahlner; Finn Bengtsson; Fredrik C Kugelberg
Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague-Dawley and Dark Agouti rats.
Chirality 2011;23(2):172-7.
2010: Maria Kingbäck; Martin Josefsson; Louise Karlsson; Johan Ahlner; Finn Bengtsson; Fredrik C Kugelberg; Björn Carlsson
Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction.
Journal of pharmaceutical and biomedical analysis 2010;53(3):583-90.
2010: Louise Karlsson; Ulrich Schmitt; Martin Josefsson; Björn Carlsson; Johan Ahlner; Finn Bengtsson; Fredrik C Kugelberg; Christoph Hiemke
Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2010;20(9):632-40.
2009: Björn Carlsson; Anita Holmgren; Johan Ahlner; Finn Bengtsson
Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19.
Journal of analytical toxicology 2009;33(2):65-76.
2009: Mikael Landén; Helena Erlandsson; Finn Bengtsson; Björn Andersch; Elias Eriksson
Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(3):585-92.
2008: Maria D Chermá; Margareta Reis; Staffan Hagg; Johan Ahlner; Finn Bengtsson
Therapeutic drug monitoring of ziprasidone in a clinical treatment setting.
Therapeutic drug monitoring 2008;30(6):682-8.
2008: Maria D Chermá; Ulla-Britt Löfgren; Göran Almkvist; Claes Hallert; Finn Bengtsson
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: a clinical and laboratory follow-up investigation.
Journal of clinical psychopharmacology 2008;28(4):424-31.
2008: Ann-Charlotte Akerblad; Finn Bengtsson; Margareta Holgersson; Lars von Knorring; Lisa Ekselius
Identification of primary care patients at risk of nonadherence to antidepressant treatment.
Patient preference and adherence 2008;2():379-86.
2007: Margareta Reis; Maria D Chermá; Björn Carlsson; Finn Bengtsson
Therapeutic drug monitoring of escitalopram in an outpatient setting.
Therapeutic drug monitoring 2007;29(6):758-66.
2006: Lars von Knorring; Ann-Charlotte Akerblad; Finn Bengtsson; A Carlsson; Lisa Ekselius
Cost of depression: effect of adherence and treatment response.
European psychiatry : the journal of the Association of European Psychiatrists 2006;21(6):349-54.
2006: Fredrik C Kugelberg; Gustav Apelqvist; Björn Carlsson; Johan Ahlner; Finn Bengtsson
Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin.
Basic & clinical pharmacology & toxicology 2006;99(1):80-8.
2006: Jan Wålinder; Jiri Prochazka; Anders Odén; Ingemar Sjödin; Marja-Liisa Dahl; Johan Ahlner; Finn Bengtsson
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Human psychopharmacology 2006;21(3):151-8.
2006: Abed Almuti Zaitoun; Gustav Apelqvist; Hanan Al Mardini; Trevor Gray; Finn Bengtsson; Christopher Oswold Record
Quantitative studies of liver atrophy after portacaval shunt in the rat.
The Journal of surgical research 2006;131(2):225-32.
2006: Ann-Charlotte Akerblad; Finn Bengtsson; Lars von Knorring; Lisa Ekselius
Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study.
International clinical psychopharmacology 2006;21(2):117-24.
2005: Fredrik C Kugelberg; Gustav Apelqvist; Cecilia Wikell; Finn Bengtsson
Open-field behavioural alterations in liver-impaired and sham-operated rats after acute exposure to the antidepressant venlafaxine.
Basic & clinical pharmacology & toxicology 2005;97(3):155-61.
2005: Margareta Reis; Jiri Prochazka; Ad Sitsen; Johan Ahlner; Finn Bengtsson
Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study.
Therapeutic drug monitoring 2005;27(4):469-77.
2005: B Isaksson; L-H Thorell; Finn Bengtsson; I Rosén; Bengt Jeppsson
Hepatic encephalopathy verified by psychometric testing and EEG in cirrhotic patients: effects of mesocaval interposition shunt or sclerotherapy.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2005;7(1):65-72.
2004: Margareta Reis; Anna Aberg-Wistedt; Hans Agren; Ann-Charlotte Akerblad; Finn Bengtsson
Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations.
Journal of affective disorders 2004;82(3):443-6.
2004: Fredrik C Kugelberg; Henrik Druid; Björn Carlsson; Johan Ahlner; Finn Bengtsson
Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats.
Journal of analytical toxicology 2004;28(8):631-7.
2004: Margareta Reis; Anna Aberg-Wistedt; Hans Agren; Peter Höglund; Ann-Charlotte Akerblad; Finn Bengtsson
Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.
Human psychopharmacology 2004;19(5):283-91.
2004: Finn Bengtsson
Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau".
Therapeutic drug monitoring 2004;26(2):145-51.
2003: Ann-Charlotte Akerblad; Finn Bengtsson; Lisa Ekselius; Lars von Knorring
Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners.
International clinical psychopharmacology 2003;18(6):347-54.
2003: Fredrik C Kugelberg; Björn Carlsson; Johan Ahlner; Finn Bengtsson
Stereoselective single-dose kinetics of citalopram and its metabolites in rats.
Chirality 2003;15(7):622-9.
2003: Margareta Reis; Jöns Lundmark; Finn Bengtsson
Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.
Therapeutic drug monitoring 2003;25(2):183-91.
2003: Daniel Ohman; Maria D Cherma; Björn Norlander; Finn Bengtsson
Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine.
Therapeutic drug monitoring 2003;25(2):174-82.
2002: Margareta Reis; Gunilla Olsson; Björn Carlsson; Jöns Lundmark; Marja-Liisa Dahl; Jan Wålinder; Johan Ahlner; Finn Bengtsson
Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting.
Journal of clinical psychopharmacology 2002;22(4):406-13.
2002: Margareta Reis; Jöns Lundmark; Henrik Björk; Finn Bengtsson
Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Therapeutic drug monitoring 2002;24(4):545-53.
2002: Elisabeth Skogh; Margareta Reis; Marja-Liisa Dahl; Jöns Lundmark; Finn Bengtsson
Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
Therapeutic drug monitoring 2002;24(4):518-26.
2002: Cecilia Wikell; Gustav Apelqvist; Stephan Hjorth; Johan Kullingsjö; Peter B F Bergqvist; Finn Bengtsson
Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2002;12(4):327-36.
2002: Fredrik C Kugelberg; Gustav Apelqvist; Finn Bengtsson
Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats.
Pharmacology & toxicology 2002;90(6):303-10.
2002: Cecilia Wikell; Chin B Eap; Martin Josefsson; Gustav Apelqvist; Johan Ahlner; Pierre Baumann; Finn Bengtsson
Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment.
Chirality 2002;14(4):347-50.
2002: Jöns Lundmark; Tove Gunnarsson; Finn Bengtsson
A possible interaction between lithium and rofecoxib.
British journal of clinical pharmacology 2002;53(4):403-4.
2002: Daniel Ohman; Björn Norlander; Curt Peterson; Finn Bengtsson
Simultaneous determination of reboxetine and O-desethylreboxetine enantiomers using enantioselective reversed-phase high-performance liquid chromatography.
Journal of chromatography. A 2002;947(2):247-54.
2001: Björn Carlsson; G Olsson; Margareta Reis; J Walinder; Conny Nordin; Jöns Lundmark; Maria Gabriella Scordo; Marja-Liisa Dahl; Finn Bengtsson; Johan Ahlner
Enantioselective analysis of citalopram and metabolites in adolescents.
Therapeutic drug monitoring 2001;23(6):658-64.
2001: Cecilia Wikell; Fredrik C Kugelberg; Stephan Hjorth; Gustav Apelqvist; Finn Bengtsson
Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy.
Clinical neuropharmacology 2001;24(6):324-33.
2001: Love Linnér; H Endersz; Daniel Ohman; Finn Bengtsson; Martin Schalling; Torgny H Svensson
Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex.
The Journal of pharmacology and experimental therapeutics 2001;297(2):540-6.
2001: Cecilia Wikell; Stephan Hjorth; Gustav Apelqvist; J Kullingsjö; Jöns Lundmark; Peter B F Bergqvist; Finn Bengtsson
Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(4):448-55.
2001: Fredrik C Kugelberg; Gustav Apelqvist; Björn Carlsson; Johan Ahlner; Finn Bengtsson
In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
British journal of pharmacology 2001;132(8):1683-90.
2001: Jöns Lundmark; Margareta Reis; Finn Bengtsson
Serum concentrations of fluoxetine in the clinical treatment setting.
Therapeutic drug monitoring 2001;23(2):139-47.
2001: Mats Humble; Susanne Bejerot; Peter B F Bergqvist; Finn Bengtsson
Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
Biological psychiatry 2001;49(4):360-8.
2001: Daniel Ohman; Björn Norlander; Curt Peterson; Finn Bengtsson
Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC.
Therapeutic drug monitoring 2001;23(1):27-34.
2000: Anna Aberg-Wistedt; Hans Agren; Lisa Ekselius; Finn Bengtsson; Ann-Charlotte Akerblad
Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
Journal of clinical psychopharmacology 2000;20(6):645-52.
2000: Gustav Apelqvist; Cecilia Wikell; Björn Carlsson; Stephan Hjorth; Peter B F Bergqvist; Johan Ahlner; Finn Bengtsson
Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.
Clinical neuropharmacology 2000;23(6):304-17.
2000: Lisa Ekselius; Finn Bengtsson; Lars von Knorring
Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality.
International clinical psychopharmacology 2000;15(5):273-8.
2000: Jöns Lundmark; Margareta Reis; Finn Bengtsson
Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting.
Therapeutic drug monitoring 2000;22(4):446-54.
2000: Jöns Lundmark; Finn Bengtsson; Conny Nordin; Margareta Reis; Jan Wålinder
Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients.
Acta psychiatrica Scandinavica 2000;101(5):354-9.
1999: Gustav Apelqvist; B Hindfelt; G Andersson; Finn Bengtsson
Altered adaptive behaviour expressed in an open-field paradigm in experimental hepatic encephalopathy.
Behavioural brain research 1999;106(1-2):165-73.
1999: Cecilia Wikell; Gustav Apelqvist; Björn Carlsson; Stephan Hjorth; Peter B F Bergqvist; Fredrik C Kugelberg; Johan Ahlner; Finn Bengtsson
Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats.
Clinical neuropharmacology 1999;22(6):327-36.
1999: Elisabeth Skogh; Finn Bengtsson; Conny Nordin
Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report.
Therapeutic drug monitoring 1999;21(5):580-2.
1999: Peter B F Bergqvist; Raffaella Carpenedo; Gustav Apelqvist; Flavio Moroni; Finn Bengtsson
Plasma and brain levels of oxindole in experimental chronic hepatic encephalopathy: effects of systemic ammonium acetate and L-tryptophan.
Pharmacology & toxicology 1999;85(3):138-43.
1999: Gustav Apelqvist; Cecilia Wikell; B Hindfelt; Peter B F Bergqvist; G Andersson; Finn Bengtsson
Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges.
Psychopharmacology 1999;143(4):408-16.
1999: B Isaksson; Björn Hultberg; L Hansson; Finn Bengtsson; Bengt Jeppsson
Effect of mesocaval interposition shunting and repeated sclerotherapy on blood levels of gastrointestinal regulatory peptides, amino acids, and lysosomal enzymes--a prospective randomised trial.
Liver 1999;19(1):3-11.
1998: AM Zaitoun; Gustav Apelqvist; Cecilia Wikell; Hanan Al Mardini; Finn Bengtsson; Christopher Oswold Record
Quantitative studies of testicular atrophy following portacaval shunt in rats.
Hepatology (Baltimore, Md.) 1998;28(6):1461-6.
1998: Cecilia Wikell; Peter B F Bergqvist; Stephan Hjorth; Gustav Apelqvist; H Björk; Finn Bengtsson
Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.
Clinical neuropharmacology 1998;21(5):296-306.
1998: Gustav Apelqvist; B Hindfelt; G Andersson; Finn Bengtsson
Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field.
Behavioural brain research 1998;93(1-2):25-32.
1998: Gustav Apelqvist; Peter B F Bergqvist; B Larsson; M Bugge; Finn Bengtsson
Regional brain serotonin receptor changes in portacaval shunted rats.
Acta physiologica Scandinavica 1998;162(4):509-16.
1997: Peter B F Bergqvist; Cecilia Wikell; Stephan Hjorth; Gustav Apelqvist; Finn Bengtsson
Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency.
Clinical neuropharmacology 1997;20(6):511-22.
1997: Peter B F Bergqvist; Stephan Hjorth; Cecilia Wikell; Gustav Apelqvist; Finn Bengtsson
p-Chloroamphetamine- and d-fenfluramine-induced brain serotonin release in experimental portal-systemic encephalopathy.
Metabolic brain disease 1997;12(3):229-36.
1997: Peter B F Bergqvist; Stephan Hjorth; Gustav Apelqvist; Finn Bengtsson
Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy.
Metabolic brain disease 1997;12(3):193-202.
1997: Peter B F Bergqvist; Margareta Some; Gustav Apelqvist; Anders Helander; Finn Bengtsson
Elevated brain 5-hydroxytryptophol levels in experimental portal-systemic encephalopathy.
Pharmacology & toxicology 1997;80(4):187-90.
1997: B Theander; Gustav Apelqvist; M Bugge; G Andersson; B Hindfelt; Finn Bengtsson
Gender and diurnal effects on specific open-field behavioral patterns in the portacaval shunted rat.
Metabolic brain disease 1997;12(1):47-59.
1997: Finn Bengtsson; Peter B F Bergqvist; Gustav Apelqvist
Brain tryptophan perturbation in hepatic encephalopathy: implications for effects by neuropsychoactive drugs in clinical practice.
Advances in experimental medicine and biology 1997;420():1-33.
1996: Peter B F Bergqvist; Stephan Hjorth; Robert Audet; Gustav Apelqvist; Finn Bengtsson; R F Butterworth
Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1996;6(4):317-22.
1996: Peter B F Bergqvist; M P Heyes; Gustav Apelqvist; R F Butterworth; Finn Bengtsson
Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;15(4):382-9.
1996: Peter B F Bergqvist; Stephan Hjorth; Gustav Apelqvist; Finn Bengtsson
Acute effects of L-tryptophan on brain extracellular 5-HT and 5-HIAA levels in chronic experimental portal-systemic encephalopathy.
Metabolic brain disease 1996;11(3):269-78.
1996: Peter B F Bergqvist; M P Heyes; Finn Bengtsson
Is quinolinic acid involved in the pathogenesis of hepatic encephalopathy?
Advances in experimental medicine and biology 1996;398():397-405.
1996: Finn Bengtsson; Peter B F Bergqvist
Neuropsychiatric implications of brain tryptophan perturbations appearing in hepatic encephalopathy.
Advances in experimental medicine and biology 1996;398():387-95.
1995: Peter B F Bergqvist; M P Heyes; M Bugge; Finn Bengtsson
Brain quinolinic acid in chronic experimental hepatic encephalopathy: effects of an exogenous ammonium acetate challenge.
Journal of neurochemistry 1995;65(5):2235-40.
1995: Peter B F Bergqvist; E R Werner; Gustav Apelqvist; M Bugge; H Wachter; Finn Bengtsson
Brain biopterin metabolism in chronic experimental hepatic encephalopathy.
Metabolic brain disease 1995;10(2):143-57.
1995: B Isaksson; Bengt Jeppsson; Finn Bengtsson; P Hannesson; P Herlin; S Bengmark
Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy--a randomized trial.
Surgery 1995;117(5):498-504.
1995: N Pantzar; Peter B F Bergqvist; M Bugge; G Olaison; S Lundin; Bengt Jeppsson; B Weström; Finn Bengtsson
Small intestinal absorption of polyethylene glycol 400 to 1,000 in the portacaval shunted rat.
Hepatology (Baltimore, Md.) 1995;21(4):1167-73.
1995: Peter B F Bergqvist; BA Vogels; D K Bosman; MA Maas; Stephan Hjorth; Robert Chamuleau; Finn Bengtsson
Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt.
Journal of neurochemistry 1995;64(3):1238-44.
1991: Finn Bengtsson; M Bugge; K H Johansen; R F Butterworth
Brain tryptophan hydroxylation in the portacaval shunted rat: a hypothesis for the regulation of serotonin turnover in vivo.
Journal of neurochemistry 1991;56(3):1069-74.
1989: M Bugge; Finn Bengtsson; H Hall; I Wedel; A Nobin; Bengt Jeppsson; P Herlin
Serotonin receptors in the brain following total hepatectomy in rats treated with branched-chain amino acids.
JPEN. Journal of parenteral and enteral nutrition 1989;13(3):235-9.
1989: Finn Bengtsson; M Bugge; P Herlin; A Nobin; Bengt Jeppsson
Serotonin metabolism in the central nervous system in portacaval shunted rats infused with fat emulsion.
JPEN. Journal of parenteral and enteral nutrition 1989;13(1):65-70.
1989: Finn Bengtsson; M Bugge; H Hall; A Nobin
Brain 5-HT1 and 5-HT2 binding sites following portacaval shunt in the rat.
Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 1989;189(4):249-56.
1989: M Bugge; Finn Bengtsson; A Nobin; Bengt Jeppsson; Björn Hultberg; T Jonung; P Herlin
The effect of ammonia infusion on brain monoamine metabolism in portacaval-shunted rats.
Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 1989;189(2):101-11.
1988: Finn Bengtsson; A Nobin; B Falck; F H Gage; B Jeppsson
Effect of oral branched chain amino acids on behavior and brain serotonin metabolism in portacaval shunted rats.
World journal of surgery 1988;12(2):246-54.
1988: Finn Bengtsson; M Bugge; A Brun; B Falck; K G Henriksson; A Nobin
The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology.
Journal of the neurological sciences 1988;83(1):109-22.
1987: M Bugge; Finn Bengtsson; A Nobin; Bengt Jeppsson; P Herlin
The turnover of brain monoamines after total hepatectomy in rats infused with branched chain amino acids.
World journal of surgery 1987;11(6):810-7.
1987: Finn Bengtsson; M Bugge; L Hansson; K Fyge; Bengt Jeppsson; A Nobin
Serotonin metabolism in the central nervous system following sepsis or portacaval shunt in the rat.
The Journal of surgical research 1987;43(5):420-9.
1987: Finn Bengtsson; M Bugge; C Vagianos; Bengt Jeppsson; A Nobin
Brain serotonin metabolism and behavior in rats with carbon tetrachloride-induced liver cirrhosis.
Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 1987;187(6):429-38.
1987: P Bartelmess; Finn Bengtsson; A Nobin; Bengt Jeppsson; P Herlin; M Bugge
The effect of blood ingestion on brain serotonin synthesis in portacaval-shunted rats.
Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 1987;187(5):353-8.
1987: M Bugge; Finn Bengtsson; A Nobin; Bengt Jeppsson; P Herlin
The effect of liver ischaemia on brain monoamine synthesis in the rat.
Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 1987;187(2):119-30.
1986: M Bugge; Finn Bengtsson; A Nobin; Bengt Jeppsson; P Herlin
Metabolism of monoamines in the brain after total hepatectomy in the rat.
Experimental neurology 1986;94(1):11-20.
1986: M Bugge; Finn Bengtsson; A Nobin; T Holmin; Bengt Jeppsson; Björn Hultberg; B Falck; P Herlin
Amino acids and indoleamines in the brain after infusion of branched-chain amino acids to rats with liver ischemia.
JPEN. Journal of parenteral and enteral nutrition 1986;10(5):474-8.
1986: Finn Bengtsson; A Nobin; B Falck; F H Gage; B Jeppsson
Portacaval shunt in the rat: selective alterations in behavior and brain serotonin.
Pharmacology, biochemistry, and behavior 1986;24(6):1611-6.
1985: Finn Bengtsson; F H Gage; B Jeppsson; A Nobin; E Rosengren
Brain monoamine metabolism and behavior in portacaval-shunted rats.
Experimental neurology 1985;90(1):21-35.